Haque 2010.

Methods	Design: parallel group randomized trial (factorial) Duration of study: not reported Follow‐up: 120 days
Participants	Country: Bangladesh Setting: community Number included in study: 248 Age: 24–60 months Sex: 121 boys, 100 girls Inclusion criteria:Ascaris infection was prerequisite for enrolment to study; children apparently healthy without a history of chronic illness; without hookworm infection, and willing to take daily β‐carotene capsule and 2 doses of albendazole during study Exclusion criteria: severe malnutrition, clinical vitamin A deficiency (as indicated by corneal involvement), chronic diseases, or persistent diarrhoea Lost at follow‐up: 27 (10.9%) Number positive for A lumbricoides: 248 Number included in review: 111
Interventions	Treatment strategy: screening and treat all included participants Group 1: albendazole 400 mg single dose + placebo (n = 55) Group 2: placebo + placebo (n = 56) Group 3: albendazole 400 mg single dose + β‐carotene (not included in review) Group 4: β‐carotene + placebo (not included in review)
Outcomes	Outcomes included:Ascaris prevalence pre‐ and post‐treatment, cure rates, pre‐ and post‐treatment AM epg, ERR Outcomes not included in review: efficacy of albendazole + β‐carotene and β‐carotene + placebo for A lumbricoides; anthelmintic efficacy for Trichuris; β‐carotene levels
Notes	Diagnostic technique: not reported Funding support: Thrasher Research Fund, USA. Eskayef Bangladesh Ltd. provided albendazole
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Block randomization was used for recruiting children in the treatment group and placebo (control) groups."
Allocation concealment (selection bias)	Unclear risk	Details not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Placebo forms for both albendazole tablets and β‐carotene capsules were of identical size, shape, and colour."
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	27 (10.9%) participants lost at follow‐up and not included in analysis.
Selective reporting (reporting bias)	High risk	Adverse events not reported.
Other bias	Low risk	The pharmaceutical industry donated the drug.